Abstract
TAK-375 (Ramelteon), a melatonin ML1/MT1 receptor agonist for the potential treatment of primary insomnia, is being developed by Takeda. Takeda submitted an NDA to the FDA for TAK-375 in September 2004.
MeSH terms
-
Animals
-
Clinical Trials as Topic
-
Humans
-
Indenes* / adverse effects
-
Indenes* / pharmacokinetics
-
Indenes* / therapeutic use
-
Receptor, Melatonin, MT1 / agonists
-
Sleep Wake Disorders / drug therapy*
-
Sleep Wake Disorders / metabolism
Substances
-
Indenes
-
Receptor, Melatonin, MT1
-
ramelteon